{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T05:23:15Z","timestamp":1790659395416,"version":"4.1.0"},"reference-count":105,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,3,28]],"date-time":"2025-03-28T00:00:00Z","timestamp":1743120000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["thelancet.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["eClinicalMedicine"],"published-print":{"date-parts":[[2025,5]]},"DOI":"10.1016\/j.eclinm.2025.103203","type":"journal-article","created":{"date-parts":[[2025,4,15]],"date-time":"2025-04-15T13:29:57Z","timestamp":1744723797000},"page":"103203","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":11,"special_numbering":"C","title":["Genetic predisposition in sarcomas: clinical implications and management"],"prefix":"10.1016","volume":"83","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5579-3728","authenticated-orcid":false,"given":"Elizabeth A.","family":"Connolly","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kjetil","family":"Boye","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sylvie","family":"Bonvalot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christian P.","family":"Kratz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2598-2325","authenticated-orcid":false,"given":"Andreas","family":"Leithner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Malkin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0557-9379","authenticated-orcid":false,"given":"Christina","family":"Messiou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aisha B.","family":"Miah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pan","family":"Pantziarka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Beate","family":"Timmermann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Winette T.A.","family":"van der Graaf","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David M.","family":"Thomas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1742-8666","authenticated-orcid":false,"given":"Silvia","family":"Stacchiotti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.eclinm.2025.103203_bib1","series-title":"WHO classification of tumours of soft tissue and bone tumours","year":"2020"},{"issue":"16","key":"10.1016\/j.eclinm.2025.103203_bib2","doi-asserted-by":"crossref","first-page":"2934","DOI":"10.1002\/cncr.33618","article-title":"Ultra-rare sarcomas: a consensus paper from the Connective Tissue Oncology Society community of experts on the incidence threshold and the list of entities","volume":"127","author":"Stacchiotti","year":"2021","journal-title":"Cancer"},{"issue":"8","key":"10.1016\/j.eclinm.2025.103203_bib3","doi-asserted-by":"crossref","first-page":"1002","DOI":"10.1634\/theoncologist.2016-0079","article-title":"Sarcomas associated with genetic cancer predisposition syndromes: a review","volume":"21","author":"Farid","year":"2016","journal-title":"Oncologist"},{"issue":"3","key":"10.1016\/j.eclinm.2025.103203_bib4","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1097\/SLA.0000000000000869","article-title":"Lessons learned from the study of 10,000 patients with soft tissue sarcoma","volume":"260","author":"Brennan","year":"2014","journal-title":"Ann Surg"},{"issue":"12","key":"10.1016\/j.eclinm.2025.103203_bib5","doi-asserted-by":"crossref","first-page":"1520","DOI":"10.1016\/j.annonc.2021.08.1995","article-title":"Bone sarcomas: ESMO-EURACAN-GENTURIS-ERN PaedCan clinical practice guideline for diagnosis, treatment and follow-up","volume":"32","author":"Strauss","year":"2021","journal-title":"Ann Oncol"},{"issue":"12","key":"10.1016\/j.eclinm.2025.103203_bib6","doi-asserted-by":"crossref","DOI":"10.3390\/ijms19123784","article-title":"Translocation-related sarcomas","volume":"19","author":"Nakano","year":"2018","journal-title":"Int J Mol Sci"},{"issue":"6629","key":"10.1016\/j.eclinm.2025.103203_bib7","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1126\/science.abj4784","article-title":"Heritable defects in telomere and mitotic function selectively predispose to sarcomas","volume":"379","author":"Ballinger","year":"2023","journal-title":"Science"},{"issue":"1","key":"10.1016\/j.eclinm.2025.103203_bib8","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1136\/jmg-2023-109269","article-title":"Prevalence and clinical implications of germline pathogenic variants in cancer predisposing genes in young patients across sarcoma subtypes","volume":"61","author":"Carvalho","year":"2023","journal-title":"J Med Genet"},{"issue":"12","key":"10.1016\/j.eclinm.2025.103203_bib9","doi-asserted-by":"crossref","first-page":"1735","DOI":"10.1001\/jamaoncol.2017.1355","article-title":"Surveillance in germline TP53 mutation carriers utilizing whole-body magnetic resonance imaging","volume":"3","author":"Ballinger","year":"2017","journal-title":"JAMA Oncol"},{"issue":"9","key":"10.1016\/j.eclinm.2025.103203_bib10","doi-asserted-by":"crossref","first-page":"1295","DOI":"10.1016\/S1470-2045(16)30249-2","article-title":"Biochemical and imaging surveillance in germline TP53 mutation carriers with Li-Fraumeni syndrome: 11 year follow-up of a prospective observational study","volume":"17","author":"Villani","year":"2016","journal-title":"Lancet Oncol"},{"issue":"1","key":"10.1016\/j.eclinm.2025.103203_bib11","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1002\/ajmg.c.30026","article-title":"Inherited predisposition to cancer: a historical overview","volume":"129C","author":"Lynch","year":"2004","journal-title":"Am J Med Genet C Semin Med Genet"},{"issue":"9","key":"10.1016\/j.eclinm.2025.103203_bib12","doi-asserted-by":"crossref","first-page":"2001","DOI":"10.1002\/ijc.21962","article-title":"Hereditary cancer predisposition in children: genetic basis and clinical implications","volume":"119","author":"Strahm","year":"2006","journal-title":"Int J Cancer"},{"issue":"8","key":"10.1016\/j.eclinm.2025.103203_bib13","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1038\/nm1087","article-title":"Cancer genes and the pathways they control","volume":"10","author":"Vogelstein","year":"2004","journal-title":"Nat Med"},{"issue":"5","key":"10.1016\/j.eclinm.2025.103203_bib14","doi-asserted-by":"crossref","first-page":"1387","DOI":"10.1002\/cncr.26390","article-title":"Sarcomas in TP53 germline mutation carriers: a review of the IARC TP53 database","volume":"118","author":"Ognjanovic","year":"2012","journal-title":"Cancer"},{"issue":"4985","key":"10.1016\/j.eclinm.2025.103203_bib15","doi-asserted-by":"crossref","first-page":"1233","DOI":"10.1126\/science.1978757","article-title":"Germ line p53 mutations in a familial syndrome of breast cancer, sarcomas, and other neoplasms","volume":"250","author":"Malkin","year":"1990","journal-title":"Science"},{"issue":"6303","key":"10.1016\/j.eclinm.2025.103203_bib16","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1038\/348747a0","article-title":"Germ-line transmission of a mutated p53 gene in a cancer-prone family with Li-Fraumeni syndrome","volume":"348","author":"Srivastava","year":"1990","journal-title":"Nature"},{"issue":"5","key":"10.1016\/j.eclinm.2025.103203_bib17","first-page":"1298","article-title":"Prevalence and diversity of constitutional mutations in the p53 gene among 21 Li-Fraumeni families","volume":"54","author":"Birch","year":"1994","journal-title":"Cancer Res"},{"issue":"1","key":"10.1016\/j.eclinm.2025.103203_bib18","first-page":"1","article-title":"Tumors associated with p53 germline mutations: a synopsis of 91 families","volume":"150","author":"Kleihues","year":"1997","journal-title":"Am J Pathol"},{"issue":"6250","key":"10.1016\/j.eclinm.2025.103203_bib19","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1038\/342705a0","article-title":"Mutations in the p53 gene occur in diverse human tumour types","volume":"342","author":"Nigro","year":"1989","journal-title":"Nature"},{"issue":"1","key":"10.1016\/j.eclinm.2025.103203_bib20","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/bjc.1997.328","article-title":"Li-Fraumeni syndrome--a molecular and clinical review","volume":"76","author":"Varley","year":"1997","journal-title":"Br J Cancer"},{"issue":"6","key":"10.1016\/j.eclinm.2025.103203_bib21","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1016\/j.cell.2004.11.006","article-title":"Gain of function of a p53 hot spot mutation in a mouse model of Li-Fraumeni syndrome","volume":"119","author":"Lang","year":"2004","journal-title":"Cell"},{"issue":"9","key":"10.1016\/j.eclinm.2025.103203_bib22","first-page":"3982","article-title":"High incidence of lung, bone, and lymphoid tumors in transgenic mice overexpressing mutant alleles of the p53 oncogene","volume":"9","author":"Lavigueur","year":"1989","journal-title":"Mol Cell Biol"},{"issue":"6","key":"10.1016\/j.eclinm.2025.103203_bib23","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1016\/j.cell.2004.11.004","article-title":"Mutant p53 gain of function in two mouse models of Li-Fraumeni syndrome","volume":"119","author":"Olive","year":"2004","journal-title":"Cell"},{"issue":"6381","key":"10.1016\/j.eclinm.2025.103203_bib24","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1038\/358015a0","article-title":"Cancer. p53, guardian of the genome","volume":"358","author":"Lane","year":"1992","journal-title":"Nature"},{"issue":"6","key":"10.1016\/j.eclinm.2025.103203_bib25","doi-asserted-by":"crossref","first-page":"946","DOI":"10.1016\/j.ccell.2024.04.009","article-title":"Understanding the complexity of p53 in a new era of tumor suppression","volume":"42","author":"Liu","year":"2024","journal-title":"Cancer Cell"},{"issue":"2","key":"10.1016\/j.eclinm.2025.103203_bib26","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1016\/j.cell.2018.03.039","article-title":"Pathogenic germline variants in 10,389 adult cancers","volume":"173","author":"Huang","year":"2018","journal-title":"Cell"},{"issue":"7","key":"10.1016\/j.eclinm.2025.103203_bib27","doi-asserted-by":"crossref","first-page":"1905","DOI":"10.1038\/s41591-024-03056-w","article-title":"Benefits for children with suspected cancer from routine whole-genome sequencing","volume":"30","author":"Hodder","year":"2024","journal-title":"Nat Med"},{"issue":"23","key":"10.1016\/j.eclinm.2025.103203_bib28","doi-asserted-by":"crossref","first-page":"3673","DOI":"10.1002\/cncr.30248","article-title":"Risks of first and subsequent cancers among TP53 mutation carriers in the National Cancer Institute Li-Fraumeni syndrome cohort","volume":"122","author":"Mai","year":"2016","journal-title":"Cancer"},{"issue":"5","key":"10.1016\/j.eclinm.2025.103203_bib29","doi-asserted-by":"crossref","first-page":"860","DOI":"10.1038\/s41416-024-02721-8","article-title":"Introduction and impact of routine whole genome sequencing in the diagnosis and management of sarcoma","volume":"131","author":"Watkins","year":"2024","journal-title":"Br J Cancer"},{"issue":"2","key":"10.1016\/j.eclinm.2025.103203_bib30","doi-asserted-by":"crossref","DOI":"10.1093\/jncics\/pkab007","article-title":"Frequency of pathogenic germline variants in cancer-susceptibility genes in the childhood cancer survivor study","volume":"5","author":"Kim","year":"2021","journal-title":"JNCI Cancer Spectr"},{"issue":"9","key":"10.1016\/j.eclinm.2025.103203_bib31","doi-asserted-by":"crossref","first-page":"1261","DOI":"10.1016\/S1470-2045(16)30147-4","article-title":"Monogenic and polygenic determinants of sarcoma risk: an international genetic study","volume":"17","author":"Ballinger","year":"2016","journal-title":"Lancet Oncol"},{"issue":"3","key":"10.1016\/j.eclinm.2025.103203_bib32","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1016\/j.annonc.2022.12.003","article-title":"Germline-focused analysis of tumour-detected variants in 49,264 cancer patients: ESMO Precision Medicine Working Group recommendations","volume":"34","author":"Kuzbari","year":"2023","journal-title":"Ann Oncol"},{"issue":"5","key":"10.1016\/j.eclinm.2025.103203_bib33","doi-asserted-by":"crossref","first-page":"724","DOI":"10.1001\/jamaoncol.2020.0197","article-title":"Frequency of pathogenic germline variants in cancer-susceptibility genes in patients with osteosarcoma","volume":"6","author":"Mirabello","year":"2020","journal-title":"JAMA Oncol"},{"issue":"6","key":"10.1016\/j.eclinm.2025.103203_bib34","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1038\/s41571-019-0179-3","article-title":"Therapeutic implications of germline genetic findings in cancer","volume":"16","author":"Thavaneswaran","year":"2019","journal-title":"Nat Rev Clin Oncol"},{"issue":"4","key":"10.1016\/j.eclinm.2025.103203_bib35","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1038\/ng.2592","article-title":"iCOGS collection provides a collaborative model","volume":"45","author":"Bahcall","year":"2013","journal-title":"Nat Genet"},{"issue":"7","key":"10.1016\/j.eclinm.2025.103203_bib36","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1038\/ng.2645","article-title":"Genome-wide association study identifies two susceptibility loci for osteosarcoma","volume":"45","author":"Savage","year":"2013","journal-title":"Nat Genet"},{"issue":"1","key":"10.1016\/j.eclinm.2025.103203_bib37","doi-asserted-by":"crossref","first-page":"3184","DOI":"10.1038\/s41467-018-05537-2","article-title":"Genome-wide association study identifies multiple new loci associated with Ewing sarcoma susceptibility","volume":"9","author":"Machiela","year":"2018","journal-title":"Nat Commun"},{"issue":"11","key":"10.1016\/j.eclinm.2025.103203_bib38","doi-asserted-by":"crossref","first-page":"1348","DOI":"10.1016\/j.annonc.2021.07.006","article-title":"Soft tissue and visceral sarcomas: ESMO-EURACAN-GENTURIS Clinical Practice Guidelines for diagnosis, treatment and follow-up(\u2606)","volume":"32","author":"Gronchi","year":"2021","journal-title":"Ann Oncol"},{"issue":"10","key":"10.1016\/j.eclinm.2025.103203_bib39","doi-asserted-by":"crossref","first-page":"1379","DOI":"10.1038\/s41431-020-0638-4","article-title":"Guidelines for the Li-Fraumeni and heritable TP53-related cancer syndromes","volume":"28","author":"Frebourg","year":"2020","journal-title":"Eur J Hum Genet"},{"key":"10.1016\/j.eclinm.2025.103203_bib40","article-title":"Nearly half of TP53 germline variants predicted to Be pathogenic in patients with osteosarcoma are de novo: a report from the children\u2019s Oncology group","volume":"4","author":"Diessner","year":"2020","journal-title":"JCO Precis Oncol"},{"issue":"12","key":"10.1016\/j.eclinm.2025.103203_bib41","doi-asserted-by":"crossref","first-page":"1800","DOI":"10.1001\/jamaoncol.2021.4398","article-title":"Analysis of the Li-Fraumeni spectrum based on an international germline TP53 variant data set: an international agency for research on cancer TP53 database analysis","volume":"7","author":"Kratz","year":"2021","journal-title":"JAMA Oncol"},{"issue":"5","key":"10.1016\/j.eclinm.2025.103203_bib42","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmg.2023.104718","article-title":"Genetic susceptibility in children, adolescents, and young adults diagnosed with soft-tissue sarcomas","volume":"66","author":"Wurtemberger","year":"2023","journal-title":"Eur J Med Genet"},{"issue":"8","key":"10.1016\/j.eclinm.2025.103203_bib43","doi-asserted-by":"crossref","first-page":"4966","DOI":"10.1245\/s10434-023-13519-y","article-title":"Surgical management of germline gastrointestinal stromal tumor","volume":"30","author":"Kwak","year":"2023","journal-title":"Ann Surg Oncol"},{"issue":"8","key":"10.1016\/j.eclinm.2025.103203_bib44","doi-asserted-by":"crossref","first-page":"1121","DOI":"10.1001\/jamaoncol.2024.1805","article-title":"Current management of desmoid tumors: a review","volume":"10","author":"Kasper","year":"2024","journal-title":"JAMA Oncol"},{"issue":"4","key":"10.1016\/j.eclinm.2025.103203_bib45","doi-asserted-by":"crossref","DOI":"10.3390\/cancers15041077","article-title":"Malignant peripheral nerve sheath tumors: latest concepts in disease pathogenesis and clinical management","volume":"15","author":"Yao","year":"2023","journal-title":"Cancers (Basel)"},{"issue":"15","key":"10.1016\/j.eclinm.2025.103203_bib46","doi-asserted-by":"crossref","first-page":"1430","DOI":"10.1056\/NEJMoa1912735","article-title":"Selumetinib in children with inoperable plexiform neurofibromas","volume":"382","author":"Gross","year":"2020","journal-title":"N Engl J Med"},{"issue":"5","key":"10.1016\/j.eclinm.2025.103203_bib47","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1016\/j.anndiagpath.2015.06.003","article-title":"PEComa: morphology and genetics of a complex tumor family","volume":"19","author":"Thway","year":"2015","journal-title":"Ann Diagn Pathol"},{"issue":"5","key":"10.1016\/j.eclinm.2025.103203_bib48","doi-asserted-by":"crossref","first-page":"726","DOI":"10.1038\/s41416-022-02059-z","article-title":"Lynch syndrome, molecular mechanisms and variant classification","volume":"128","author":"Abildgaard","year":"2023","journal-title":"Br J Cancer"},{"issue":"4","key":"10.1016\/j.eclinm.2025.103203_bib49","doi-asserted-by":"crossref","first-page":"566","DOI":"10.1038\/s41591-020-0805-8","article-title":"Neoadjuvant immunotherapy leads to pathological responses in MMR-proficient and MMR-deficient early-stage colon cancers","volume":"26","author":"Chalabi","year":"2020","journal-title":"Nat Med"},{"issue":"21","key":"10.1016\/j.eclinm.2025.103203_bib50","doi-asserted-by":"crossref","first-page":"1949","DOI":"10.1056\/NEJMoa2400634","article-title":"Neoadjuvant immunotherapy in locally advanced mismatch repair-deficient colon cancer","volume":"390","author":"Chalabi","year":"2024","journal-title":"N Engl J Med"},{"issue":"4","key":"10.1016\/j.eclinm.2025.103203_bib51","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1111\/his.14377","article-title":"Mismatch repair deficiency is rare in bone and soft tissue tumors","volume":"79","author":"Lam","year":"2021","journal-title":"Histopathology"},{"issue":"3","key":"10.1016\/j.eclinm.2025.103203_bib52","doi-asserted-by":"crossref","DOI":"10.1016\/j.berh.2020.101505","article-title":"Multiple hereditary exostoses and enchondromatosis","volume":"34","author":"Jurik","year":"2020","journal-title":"Best Pract Res Clin Rheumatol"},{"issue":"12","key":"10.1016\/j.eclinm.2025.103203_bib53","doi-asserted-by":"crossref","first-page":"1771","DOI":"10.1634\/theoncologist.2011-0200","article-title":"Incidence, predictive factors, and prognosis of chondrosarcoma in patients with Ollier disease and Maffucci syndrome: an international multicenter study of 161 patients","volume":"16","author":"Verdegaal","year":"2011","journal-title":"Oncologist"},{"issue":"5","key":"10.1016\/j.eclinm.2025.103203_bib54","doi-asserted-by":"crossref","first-page":"1093","DOI":"10.1002\/ajmg.a.61530","article-title":"Natural history of Ollier disease and Maffucci syndrome: patient survey and review of clinical literature","volume":"182","author":"El Abiad","year":"2020","journal-title":"Am J Med Genet A"},{"issue":"1","key":"10.1016\/j.eclinm.2025.103203_bib55","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1007\/s10147-022-02267-w","article-title":"Secondary osteosarcoma: a challenge indeed","volume":"28","author":"Meazza","year":"2023","journal-title":"Int J Clin Oncol"},{"issue":"24","key":"10.1016\/j.eclinm.2025.103203_bib56","doi-asserted-by":"crossref","first-page":"2728","DOI":"10.1200\/JCO.19.02760","article-title":"Pathogenic germline mutations in DNA repair genes in combination with cancer treatment exposures and risk of subsequent neoplasms among long-term survivors of childhood cancer","volume":"38","author":"Qin","year":"2020","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.eclinm.2025.103203_bib57","doi-asserted-by":"crossref","first-page":"236","DOI":"10.18632\/oncotarget.28387","article-title":"Genetic modifiers of p53: opportunities for breast cancer therapies","volume":"14","author":"Majhi","year":"2023","journal-title":"Oncotarget"},{"issue":"1","key":"10.1016\/j.eclinm.2025.103203_bib58","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1186\/s13063-024-07929-w","article-title":"Cancer Precision-Prevention trial of Metformin in adults with Li Fraumeni syndrome (MILI) undergoing yearly MRI surveillance: a randomised controlled trial protocol","volume":"25","author":"Dixon-Zegeye","year":"2024","journal-title":"Trials"},{"key":"10.1016\/j.eclinm.2025.103203_bib59","doi-asserted-by":"crossref","first-page":"615","DOI":"10.2147\/CMAR.S351284","article-title":"Management strategies for adults with locally advanced, unresectable or metastatic malignant perivascular epithelioid cell tumor (PEComa): challenges and solutions","volume":"15","author":"Czarnecka","year":"2023","journal-title":"Cancer Manag Res"},{"issue":"33","key":"10.1016\/j.eclinm.2025.103203_bib60","doi-asserted-by":"crossref","first-page":"3660","DOI":"10.1200\/JCO.21.01728","article-title":"Nab-sirolimus for patients with malignant perivascular epithelioid cell tumors","volume":"39","author":"Wagner","year":"2021","journal-title":"J Clin Oncol"},{"issue":"1","key":"10.1016\/j.eclinm.2025.103203_bib61","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1016\/j.annonc.2021.09.005","article-title":"Gastrointestinal stromal tumours: ESMO-EURACAN-GENTURIS Clinical Practice Guidelines for diagnosis, treatment and follow-up","volume":"33","author":"Casali","year":"2022","journal-title":"Ann Oncol"},{"issue":"10","key":"10.1016\/j.eclinm.2025.103203_bib62","doi-asserted-by":"crossref","DOI":"10.1634\/theoncologist.2019-0418","article-title":"A phase I study of binimetinib (MEK162) combined with pexidartinib (PLX3397) in patients with advanced gastrointestinal stromal tumor","volume":"24","author":"Rosenbaum","year":"2019","journal-title":"Oncologist"},{"issue":"13","key":"10.1016\/j.eclinm.2025.103203_bib63","doi-asserted-by":"crossref","first-page":"1865","DOI":"10.2169\/internalmedicine.2321-18","article-title":"Gastrointestinal stromal tumor in a patient with neurofibromatosis type 1 that was successfully treated with regorafenib","volume":"58","author":"Fujimi","year":"2019","journal-title":"Intern Med"},{"issue":"7","key":"10.1016\/j.eclinm.2025.103203_bib64","doi-asserted-by":"crossref","first-page":"922","DOI":"10.1001\/jamaoncol.2016.0256","article-title":"Molecular subtypes of KIT\/PDGFRA wild-type gastrointestinal stromal tumors: a report from the national institutes of health gastrointestinal stromal tumor clinic","volume":"2","author":"Boikos","year":"2016","journal-title":"JAMA Oncol"},{"issue":"16_suppl","key":"10.1016\/j.eclinm.2025.103203_bib65","doi-asserted-by":"crossref","first-page":"11502","DOI":"10.1200\/JCO.2024.42.16_suppl.11502","article-title":"Updated efficacy results of olverembatinib (HQP1351) in patients with tyrosine kinase inhibitor (TKI)-resistant succinate dehydrogenase (SDH)-deficient gastrointestinal stromal tumors (GIST) and paraganglioma","volume":"42","author":"Qiu","year":"2024","journal-title":"J Clin Oncol"},{"issue":"4","key":"10.1016\/j.eclinm.2025.103203_bib66","doi-asserted-by":"crossref","DOI":"10.3390\/ph16040614","article-title":"Agnostic approvals in Oncology: getting the right drug to the right patient with the right genomics","volume":"16","author":"Tateo","year":"2023","journal-title":"Pharmaceuticals"},{"key":"10.1016\/j.eclinm.2025.103203_bib67","doi-asserted-by":"crossref","first-page":"e2400047","DOI":"10.1200\/PO.24.00047","article-title":"Microsatellite instability and clinical use in sarcomas: systematic review and illustrative case report","volume":"8","author":"Fernandes","year":"2024","journal-title":"JCO Precis Oncol"},{"key":"10.1016\/j.eclinm.2025.103203_bib68","doi-asserted-by":"crossref","first-page":"e2200068","DOI":"10.1200\/PO.22.00068","article-title":"Soft tissue leiomyosarcoma with microsatellite instability, high tumor mutational burden, and programmed death ligand-1 expression showing pathologic complete response to pembrolizumab: a case report","volume":"6","author":"Tay","year":"2022","journal-title":"JCO Precis Oncol"},{"key":"10.1016\/j.eclinm.2025.103203_bib69","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejca.2024.115196","article-title":"Sarcomas developed in patients with Lynch Syndrome are enriched in pleomorphic soft-tissue sarcomas and are sensitive to immunotherapy","volume":"216","author":"Poumeaud","year":"2025","journal-title":"Eur J Cancer"},{"issue":"23","key":"10.1016\/j.eclinm.2025.103203_bib70","doi-asserted-by":"crossref","first-page":"4770","DOI":"10.1158\/1078-0432.CCR-23-0411","article-title":"Efficacy of nivolumab in pediatric cancers with high mutation burden and mismatch repair deficiency","volume":"29","author":"Das","year":"2023","journal-title":"Clin Cancer Res"},{"issue":"5","key":"10.1016\/j.eclinm.2025.103203_bib71","doi-asserted-by":"crossref","first-page":"668","DOI":"10.1016\/S1470-2045(24)00026-3","article-title":"Clinical and biological landscape of constitutional mismatch-repair deficiency syndrome: an International Replication Repair Deficiency Consortium cohort study","volume":"25","author":"Ercan","year":"2024","journal-title":"Lancet Oncol"},{"issue":"10","key":"10.1016\/j.eclinm.2025.103203_bib72","doi-asserted-by":"crossref","first-page":"828","DOI":"10.1016\/j.trecan.2023.07.002","article-title":"Tumor-agnostic drug development in dMMR\/MSI-H solid tumors","volume":"9","author":"Bhamidipati","year":"2023","journal-title":"Trends Cancer"},{"issue":"7997","key":"10.1016\/j.eclinm.2025.103203_bib73","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1038\/d41586-024-00216-3","article-title":"Forget lung, breast or prostate cancer: why tumour naming needs to change","volume":"626","author":"Andre","year":"2024","journal-title":"Nature"},{"issue":"14","key":"10.1016\/j.eclinm.2025.103203_bib74","doi-asserted-by":"crossref","first-page":"1529","DOI":"10.1200\/JCO.21.02112","article-title":"Cancer risks associated with BRCA1 and BRCA2 pathogenic variants","volume":"40","author":"Li","year":"2022","journal-title":"J Clin Oncol"},{"issue":"14","key":"10.1016\/j.eclinm.2025.103203_bib75","doi-asserted-by":"crossref","first-page":"3881","DOI":"10.1158\/1078-0432.CCR-19-3959","article-title":"Genomic landscape of uterine sarcomas defined through prospective clinical sequencing","volume":"26","author":"Hensley","year":"2020","journal-title":"Clin Cancer Res"},{"issue":"7","key":"10.1016\/j.eclinm.2025.103203_bib76","doi-asserted-by":"crossref","first-page":"973","DOI":"10.1634\/theoncologist.2018-0448","article-title":"BRCA1\/2 functional loss defines a targetable subset in leiomyosarcoma","volume":"24","author":"Seligson","year":"2019","journal-title":"Oncologist"},{"issue":"4","key":"10.1016\/j.eclinm.2025.103203_bib77","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1016\/j.amjms.2018.04.015","article-title":"BRCA2 loss-of-function and high sensitivity to cisplatin-based chemotherapy in a patient with a pleomorphic soft tissue sarcoma: effect of genomic medicine","volume":"356","author":"Tlemsani","year":"2018","journal-title":"Am J Med Sci"},{"issue":"4","key":"10.1016\/j.eclinm.2025.103203_bib78","doi-asserted-by":"crossref","first-page":"576","DOI":"10.1038\/s41416-021-01438-2","article-title":"TP53 mutations increase radioresistance in rhabdomyosarcoma and Ewing sarcoma","volume":"125","author":"Casey","year":"2021","journal-title":"Br J Cancer"},{"key":"10.1016\/j.eclinm.2025.103203_bib79","doi-asserted-by":"crossref","DOI":"10.3389\/fped.2020.570084","article-title":"DNA repair syndromes and cancer: insights into genetics and phenotype patterns","volume":"8","author":"Sharma","year":"2020","journal-title":"Front Pediatr"},{"issue":"6","key":"10.1016\/j.eclinm.2025.103203_bib80","doi-asserted-by":"crossref","first-page":"954","DOI":"10.1038\/sj.onc.1205143","article-title":"Werner and Bloom helicases are involved in DNA repair in a complementary fashion","volume":"21","author":"Imamura","year":"2002","journal-title":"Oncogene"},{"issue":"5","key":"10.1016\/j.eclinm.2025.103203_bib81","doi-asserted-by":"crossref","DOI":"10.3390\/cells12050820","article-title":"Increased radiation sensitivity in patients with phelan-McDermid syndrome","volume":"12","author":"Jesse","year":"2023","journal-title":"Cells"},{"issue":"2","key":"10.1016\/j.eclinm.2025.103203_bib82","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1016\/S1470-2045(16)30648-9","article-title":"A genome-based model for adjusting radiotherapy dose (GARD): a retrospective, cohort-based study","volume":"18","author":"Scott","year":"2017","journal-title":"Lancet Oncol"},{"issue":"10","key":"10.1016\/j.eclinm.2025.103203_bib83","doi-asserted-by":"crossref","DOI":"10.1016\/j.tranon.2021.101165","article-title":"Genomic identification of sarcoma radiosensitivity and the clinical implications for radiation dose personalization","volume":"14","author":"Yang","year":"2021","journal-title":"Transl Oncol"},{"issue":"2","key":"10.1016\/j.eclinm.2025.103203_bib84","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1016\/j.ijrobp.2009.06.014","article-title":"A gene expression model of intrinsic tumor radiosensitivity: prediction of response and prognosis after chemoradiation","volume":"75","author":"Eschrich","year":"2009","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"4","key":"10.1016\/j.eclinm.2025.103203_bib85","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1016\/S1470-2045(11)70061-4","article-title":"Proportion of second cancers attributable to radiotherapy treatment in adults: a cohort study in the US SEER cancer registries","volume":"12","author":"Berrington de Gonzalez","year":"2011","journal-title":"Lancet Oncol"},{"issue":"21","key":"10.1016\/j.eclinm.2025.103203_bib86","doi-asserted-by":"crossref","first-page":"2345","DOI":"10.1200\/JCO.2014.59.5728","article-title":"Revisiting Li-Fraumeni syndrome from TP53 mutation carriers","volume":"33","author":"Bougeard","year":"2015","journal-title":"J Clin Oncol"},{"issue":"12","key":"10.1016\/j.eclinm.2025.103203_bib87","doi-asserted-by":"crossref","first-page":"e562","DOI":"10.1016\/S1470-2045(21)00425-3","article-title":"Avoidance or adaptation of radiotherapy in patients with cancer with Li-Fraumeni and heritable TP53-related cancer syndromes","volume":"22","author":"Thariat","year":"2021","journal-title":"Lancet Oncol"},{"issue":"4","key":"10.1016\/j.eclinm.2025.103203_bib88","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1007\/s00066-012-0274-1","article-title":"Proton beam therapy for malignancy in Bloom syndrome","volume":"189","author":"Mizumoto","year":"2013","journal-title":"Strahlenther Onkol"},{"issue":"6","key":"10.1016\/j.eclinm.2025.103203_bib89","doi-asserted-by":"crossref","first-page":"1524","DOI":"10.4103\/jcrt.JCRT_449_19","article-title":"Re-irradiation using proton therapy for radiation-induced secondary cancer with Li-Fraumeni syndrome: a case report and review of literature","volume":"16","author":"Iwasaki","year":"2020","journal-title":"J Cancer Res Ther"},{"issue":"1","key":"10.1016\/j.eclinm.2025.103203_bib90","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1007\/s10549-020-05612-7","article-title":"Frequency of radiation-induced malignancies post-adjuvant radiotherapy for breast cancer in patients with Li-Fraumeni syndrome","volume":"181","author":"Le","year":"2020","journal-title":"Breast Cancer Res Treat"},{"issue":"12","key":"10.1016\/j.eclinm.2025.103203_bib91","doi-asserted-by":"crossref","first-page":"2455","DOI":"10.1038\/bjc.2013.228","article-title":"Second and subsequent tumours among 1927 retinoblastoma patients diagnosed in Britain 1951-2004","volume":"108","author":"MacCarthy","year":"2013","journal-title":"Br J Cancer"},{"issue":"10","key":"10.1016\/j.eclinm.2025.103203_bib92","doi-asserted-by":"crossref","first-page":"e469","DOI":"10.1016\/S1470-2045(22)00447-8","article-title":"European Society for Radiotherapy and Oncology and European Organisation for Research and Treatment of Cancer consensus on re-irradiation: definition, reporting, and clinical decision making","volume":"23","author":"Andratschke","year":"2022","journal-title":"Lancet Oncol"},{"issue":"11","key":"10.1016\/j.eclinm.2025.103203_bib93","doi-asserted-by":"crossref","first-page":"e38","DOI":"10.1158\/1078-0432.CCR-17-0408","article-title":"Cancer screening recommendations for individuals with Li-Fraumeni syndrome","volume":"23","author":"Kratz","year":"2017","journal-title":"Clin Cancer Res"},{"issue":"6","key":"10.1016\/j.eclinm.2025.103203_bib94","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1016\/S1470-2045(11)70119-X","article-title":"Biochemical and imaging surveillance in germline TP53 mutation carriers with Li-Fraumeni syndrome: a prospective observational study","volume":"12","author":"Villani","year":"2011","journal-title":"Lancet Oncol"},{"issue":"5","key":"10.1016\/j.eclinm.2025.103203_bib95","doi-asserted-by":"crossref","DOI":"10.3390\/jcm13051223","article-title":"Whole-body MRI screening for carriers of germline TP53 mutations-A systematic review and meta-analysis","volume":"13","author":"Temperley","year":"2024","journal-title":"J Clin Med"},{"issue":"12","key":"10.1016\/j.eclinm.2025.103203_bib96","doi-asserted-by":"crossref","first-page":"1640","DOI":"10.1001\/jamaoncol.2017.1350","article-title":"Prevalence of cancer at baseline screening in the national cancer institute Li-Fraumeni syndrome cohort","volume":"3","author":"Mai","year":"2017","journal-title":"JAMA Oncol"},{"issue":"3","key":"10.1016\/j.eclinm.2025.103203_bib97","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1148\/radiol.2021201740","article-title":"Oncologically relevant findings reporting and data system (ONCO-RADS): guidelines for the acquisition, interpretation, and reporting of whole-body MRI for cancer screening","volume":"299","author":"Petralia","year":"2021","journal-title":"Radiology"},{"issue":"5","key":"10.1016\/j.eclinm.2025.103203_bib98","doi-asserted-by":"crossref","DOI":"10.1148\/ryai.2021200279","article-title":"Accelerating whole-body diffusion-weighted MRI with deep learning-based denoising image filters","volume":"3","author":"Zormpas-Petridis","year":"2021","journal-title":"Radiol Artif Intell"},{"issue":"3","key":"10.1016\/j.eclinm.2025.103203_bib99","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1007\/s10689-017-9965-1","article-title":"Baseline results from the UK SIGNIFY study: a whole-body MRI screening study in TP53 mutation carriers and matched controls","volume":"16","author":"Saya","year":"2017","journal-title":"Fam Cancer"},{"issue":"12","key":"10.1016\/j.eclinm.2025.103203_bib100","doi-asserted-by":"crossref","first-page":"1634","DOI":"10.1001\/jamaoncol.2017.1968","article-title":"Baseline surveillance in Li-Fraumeni syndrome using whole-body magnetic resonance imaging: a meta-analysis","volume":"3","author":"Ballinger","year":"2017","journal-title":"JAMA Oncol"},{"issue":"8","key":"10.1016\/j.eclinm.2025.103203_bib102","doi-asserted-by":"crossref","first-page":"1060","DOI":"10.1001\/jamaoncol.2024.1878","article-title":"Performance of tumor surveillance for children with cancer predisposition","volume":"10","author":"Blake","year":"2024","journal-title":"JAMA Oncol"},{"issue":"24","key":"10.1016\/j.eclinm.2025.103203_bib103","first-page":"56","article-title":"Scanxiety. Fear of a postcancer ritual","volume":"177","author":"Feiler","year":"2011","journal-title":"Time"},{"issue":"9","key":"10.1016\/j.eclinm.2025.103203_bib104","doi-asserted-by":"crossref","first-page":"2943","DOI":"10.1002\/cam4.3889","article-title":"The patient perspective in the era of personalized medicine: what about scanxiety?","volume":"10","author":"Custers","year":"2021","journal-title":"Cancer Med"},{"issue":"4","key":"10.1016\/j.eclinm.2025.103203_bib105","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1136\/jmedgenet-2019-106407","article-title":"Psychosocial effects of whole-body MRI screening in adult high-risk pathogenic TP53 mutation carriers: a case-controlled study (SIGNIFY)","volume":"57","author":"Bancroft","year":"2020","journal-title":"J Med Genet"},{"issue":"3","key":"10.1016\/j.eclinm.2025.103203_bib106","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1007\/s10689-016-9964-7","article-title":"Psychosocial morbidity in TP53 mutation carriers: is whole-body cancer screening beneficial?","volume":"16","author":"McBride","year":"2017","journal-title":"Fam Cancer"}],"container-title":["eClinicalMedicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S258953702500135X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S258953702500135X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,2]],"date-time":"2025-10-02T17:24:24Z","timestamp":1759425864000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S258953702500135X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5]]},"references-count":105,"alternative-id":["S258953702500135X"],"URL":"https:\/\/doi.org\/10.1016\/j.eclinm.2025.103203","relation":{},"ISSN":["2589-5370"],"issn-type":[{"value":"2589-5370","type":"print"}],"subject":[],"published":{"date-parts":[[2025,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Genetic predisposition in sarcomas: clinical implications and management","name":"articletitle","label":"Article Title"},{"value":"eClinicalMedicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.eclinm.2025.103203","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"103203"}}